SmallCapReview.com has been a leading site for information on small cap stocks and penny stocks since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Teva Pharmaceutical Industries (Nasdaq: TEVA) $56.84. Announced yesterday after market close an updated strategy, highlighting key opportunities for growth and announcing its long-term goals of reaching revenues of $31 billion and non-GAAP net income of $6.8 billion, or 22% of revenues, by 2015.
"In the years to come, Teva will seek to extend our global leadership and deliver profitable growth, doubling our revenues by 2015 and reaching net income margins of 22%," said Shlomo Yanai, Teva's President and CEO. "Our core business, generics, will continue to drive our growth. At the same time, we will continue to expand our branded business, further leveraging the diversity of our balanced business model.”
What They Do: Teva Pharmaceutical Industries Ltd., headquartered in Israel, is the world's leading generic pharmaceutical company and is among the top 20 pharmaceutical companies in the world.
BJ's Restaurants (Nasdaq: BJRI) $18.80. Announced yesterday after market close that it will be presenting at two investor conferences during the month of January. The Company also reported preliminary, unaudited revenues for the fourth quarter of fiscal 2009 that ended on Tuesday, December 29, 2009. When compared to the same quarter of fiscal 2008 that ended on Tuesday, December 30, 2008, revenues for the fourth quarter increased approximately 13.4% to $112.6 million compared to $99.3 million for the same quarter last year. Comparable restaurant sales decreased approximately 0.2% during the fourth quarter, compared to a decrease of 0.7% during the same quarter last year.
For the full fiscal year of 2009, revenues increased approximately 14.1% to $426.7 million compared to $374.1 million for fiscal 2008. Comparable restaurant sales decreased approximately 0.8% during fiscal 2009, compared to a decrease of 0.3% during fiscal 2008. As in prior years, final financial results for the fourth quarter of fiscal 2009 are currently expected to be released in mid-February 2010 after the completion of the Company's annual independent audit.
What They Do: BJ's Restaurants, Inc. currently owns and operates 92 casual dining restaurants under the BJ's Restaurant & Brewery, BJ's Restaurant & Brewhouse or BJ's Pizza & Grill brand names. BJ's restaurants offer an innovative and broad menu featuring award-winning, signature deep-dish pizza complemented with generously portioned salads, appetizers, sandwiches, soups, pastas, entrees and desserts.
BioCryst Pharmaceuticals (Nasdaq: BCRX) $7.49. Today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.
"Green Cross has rapidly prepared their regulatory filing, the second application of what we hope will be many for marketing approvals of peramivir," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "BioCryst is focused on completing the development of i.v. peramivir as a treatment for hospitalized patients with seasonal influenza in the U.S. Additionally, we continue to work with other governments and our global network of partners to provide i.v. peramivir as a treatment option in the event of another wave of severe influenza during the current H1N1 pandemic, and on an ongoing basis for future influenza seasons through traditional regulatory approvals."
What They Do: BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases.
Alnylam Pharmaceuticals (Nasdaq: ALNY) $18.61. Today announced that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics. The new data document a key mechanism for endogenous targeting of LNPs to the liver, provide alternative targeting strategies for the hepatic delivery of RNAi therapeutics, and highlight potential targeting approaches for delivery to non-hepatic tissues and cell types.
What They Do: Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
